Max Chat
Company Analysis Suven Pharmaceuticals Limited
1. Summary
Advantages
- The company's current efficiency (ROE=15.86%) is higher than the sector average (ROE=3.58%)
Disadvantages
- Price (1003.85 βΉ) is higher than fair price (180.16 βΉ)
- Dividends (0%) are below the sector average (0.6581%).
- The stock's return over the last year (1.02%) is lower than the sector average (20.74%).
- Current debt level 3.07% has increased over 5 years from 0%.
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Suven Pharmaceuticals Limited | Healthcare | Index | |
|---|---|---|---|
| 7 days | 5.9% | 3.3% | 3.3% |
| 90 days | -6.5% | 8.9% | 8.3% |
| 1 year | 1% | 20.7% | 6.1% |
SUVENPHAR vs Sector: Suven Pharmaceuticals Limited has significantly underperformed the "Healthcare" sector by -19.71% over the past year.
SUVENPHAR vs Market: Suven Pharmaceuticals Limited has significantly underperformed the market by -5.05% over the past year.
Stable price: SUVENPHAR is not significantly more volatile than the rest of the market on "Bombay Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: SUVENPHAR with weekly volatility of 0.0197% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (1003.85 βΉ) is higher than the fair price (180.16 βΉ).
Price is higher than fair: The current price (1003.85 βΉ) is 82.1% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (55.03) is lower than that of the sector as a whole (56.1).
P/E vs Market: The company's P/E (55.03) is higher than that of the market as a whole (44.6).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (8.06) is lower than that of the sector as a whole (8.11).
P/BV vs Market: The company's P/BV (8.06) is higher than that of the market as a whole (5.33).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (15.95) is lower than that of the sector as a whole (17.81).
P/S vs Market: The company's P/S indicator (15.95) is higher than that of the market as a whole (8.99).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (19.55) is higher than that of the sector as a whole (4.22).
EV/Ebitda vs Market: The company's EV/Ebitda (19.55) is higher than that of the market as a whole (15.13).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -1.05% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-1.05%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-17.15%).
5.4. ROE
ROE vs Sector: The company's ROE (15.86%) is higher than that of the sector as a whole (3.58%).
ROE vs Market: The company's ROE (15.86%) is higher than that of the market as a whole (-1.52%).
5.5. ROA
ROA vs Sector: The company's ROA (14.23%) is higher than that of the sector as a whole (3.38%).
ROA vs Market: The company's ROA (14.23%) is higher than that of the market as a whole (7.42%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (13.38%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (13.44%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.6581%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 0% has been steadily paid over the past 7 years, DSI=0.75.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 3 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (49.52%) are at a comfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
